about
EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guideSalicylates inhibit T cell adhesion on endothelium under nonstatic conditions: induction of L-selectin shedding by a tyrosine kinase-dependent mechanismInfluence of geolocation and ethnicity on the phenotypic expression of primary Sjögren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium.Identification of tear lipocalin as a novel autoantigen target in Sjögren's syndrome.Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines.Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome.Long-term immunologic effects of thymectomy in patients with myasthenia gravis.Role of CD30+ T cells in rheumatoid arthritis: a counter-regulatory paradigm for Th1-driven diseases.Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study.The microbial capsular polysaccharide galactoxylomannan inhibits IL-17A production in circulating T cells from rheumatoid arthritis patients.Cardiovascular disease in systemic sclerosis.The role of T cell cytokines in modulating joint inflammation in rheumatoid arthritis.Drugs in induction and treatment of idiopathic inflammatory myopathiesAnti-ribosomal P protein antibodies detected by immunoblotting in patients with connective tissue diseases: their specificity for SLE and association with IgG anticardiolipin antibodiesEndothelial dysfunction in young patients with rheumatoid arthritis and low disease activity.T cell response to anti-CD3 antibody in Down's syndromeDetection of anti-ribosome antibodies: a long story of lights and shadows.Basis for defective proliferation of peripheral blood T cells to anti-CD2 antibodies in primary Sjögren's syndrome.Telocytes in minor salivary glands of primary Sjögren's syndrome: association with the extent of inflammation and ectopic lymphoid neogenesis.Accelerated atherosclerosis in autoimmune rheumatic diseases.Autoantibodies profile in the sera of patients with Sjogren's syndrome: the ANA evaluation--a homogeneous, multiplexed systemThe diagnostic utility of anti-cyclic citrullinated peptide antibodies, matrix metalloproteinase-3, rheumatoid factor, erythrocyte sedimentation rate, and C-reactive protein in patients with erosive and non-erosive rheumatoid arthritis.Patient-reported impact of spondyloarthritis on work disability and working life: the ATLANTIS survey.Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study.Evaluation of current methods for the measurement of serum anti double-stranded DNA antibodies.Precocious atherosclerosis in rheumatoid arthritis: role of traditional and disease-related cardiovascular risk factors.Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids.Mobilization of lymphatic endothelial precursor cells and lymphatic neovascularization in primary Sjögren's syndrome.Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study.Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.How early is the atherosclerotic risk in rheumatoid arthritis?Cardiac involvement in systemic rheumatic diseases: An update.Inflammatory and autoimmune mechanisms in the induction of atherosclerotic damage in systemic rheumatic diseases: two faces of the same coin.Atherosclerotic vascular damage and rheumatoid arthritis: a complex but intriguing link.Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy.Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature.Diagnosis and classification of autoimmune hypophysitis.Altered immunoregulation in rheumatoid arthritis: the role of regulatory T cells and proinflammatory Th17 cells and therapeutic implications.Role of regulatory T cells in rheumatoid arthritis: facts and hypothesis.Prevalence and significance of anti-saccharomyces cerevisiae antibodies in primary Sjögren's syndrome.
P50
Q26778262-ACA850C2-AEC9-4DE7-92E3-F9AFDB5B093FQ28174985-F1C219D9-9BDC-45C7-9A03-97013F35302AQ31145428-45A2F236-75B1-4C66-BB28-8F4F4BC83EC3Q33225952-9725E571-CA4F-4CEA-9FED-716A2C9CFF6DQ33567294-1ECBE136-E60B-4C6A-A947-4FEC2287336AQ33578726-F80B2B10-AAEF-478A-8125-DD94AF446286Q33862298-4522F14F-37A6-4239-9593-79F991823A84Q34207556-A5575F4C-71EC-4913-A5AA-766348F11B2EQ34486262-336107C1-D73E-4F23-B73A-9E6C987C2279Q34544926-E5210A23-130B-46D5-9D2B-F21432726643Q34947193-CED00AB4-19E9-4636-BB6B-18CF4EC0C0C7Q35010499-64E9056E-BFAD-48D9-9F39-56384627E20BQ35281940-FC1A09FF-9E68-4B31-9B66-2CA7D9623453Q35549039-BEFB1709-3528-49C4-BFFF-F65D9B303AE5Q35553196-FB5DC46F-4B8F-4D2B-B416-F6E5521FE568Q35603998-C24F3BFC-C48E-4562-A917-4B05BE181A67Q35636930-A9006BC5-3972-4BA2-B5A5-2630B9312593Q35817196-9F986206-3E0E-48FB-BD32-30D0B421D909Q35879544-75965E79-89B1-46AC-A51E-B28A414AE9F9Q36318870-01C2E84E-A65E-4C3D-86DE-FEE7294C8848Q36509933-8BBD899B-5AE9-48BA-AF9B-A669697B83CAQ36509983-792B55C1-FE50-4CAF-84BF-1F3C794EAB6BQ36758296-18D5FA2D-D785-4FB4-AABB-4BBE8CE7B7F1Q36903191-1B83A977-5185-4DB9-8CC2-0F9D22735246Q36929138-AE6324CE-DC9D-4910-8ABD-447C67B66735Q36951050-AA8B92DF-6D8C-4CAE-B1E1-BF3E5E9B683AQ37199920-247302D1-CB0D-4409-8E6F-9160FF062510Q37446596-3BD7CA52-8E9E-4542-9E39-3E9B6F34F33EQ37691074-1F1685C8-416B-4A6D-B94D-498C9BE8A52CQ37715956-256D66D2-8F6F-4781-BA0B-4861042FF7FAQ37764546-A4B9FCB4-532B-4EEC-946D-0CC8B3A26221Q37778555-18D19D53-68E9-4ED6-A9FD-4C304FFC2521Q37782589-D368035A-C134-47B9-8AFC-FB41A34E1D1BQ37786648-34462031-E3B8-4C69-8DAB-A9A7DAE8A9DAQ37829385-60DA2926-715C-4EA0-8C84-81852DF48A3AQ37991040-A32177F7-182B-43D8-843C-C2AC4EDEC809Q38179187-D4DAA561-1CD4-4CF1-9607-CAFA3AC82073Q38445764-E4E4682F-393F-4FAE-B1D3-3EDECEEAEDF1Q38497370-CDDCF4D9-EB59-43E3-B58D-6CFAC1F90FD7Q38700720-D21DE85F-6B44-4D43-8160-8295A7265465
P50
description
forsker
@nb
researcher
@en
ricercatore
@it
name
Roberto Gerli
@da
Roberto Gerli
@de
Roberto Gerli
@en
Roberto Gerli
@fr
Roberto Gerli
@nb
Roberto Gerli
@nl
Roberto Gerli
@nn
Roberto Gerli
@sv
type
label
Roberto Gerli
@da
Roberto Gerli
@de
Roberto Gerli
@en
Roberto Gerli
@fr
Roberto Gerli
@nb
Roberto Gerli
@nl
Roberto Gerli
@nn
Roberto Gerli
@sv
prefLabel
Roberto Gerli
@da
Roberto Gerli
@de
Roberto Gerli
@en
Roberto Gerli
@fr
Roberto Gerli
@nb
Roberto Gerli
@nl
Roberto Gerli
@nn
Roberto Gerli
@sv
P106
P2038
Roberto_Gerli
P21
P214
7383147665837760670008
P31
P496
0000-0002-4684-575X
P5008
P735
P7859
lccn-n2016189016